Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

Li, Lake; Hai, Jian; Li, Zhiqiang; Zhang, Yongli; Peng, Hua; Li, Kun; Weng, Xiaogang

doi:10.1016/j.fct.2013.08.036

Cited by 125 publications

(79 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of resveratrol anti-inflammatory properties, it is assumed that resveratrol supplementation might be effective in managing NAFLD and restraining its progression. Previous animal studies showed that resveratrol protects the liver against steatosis and fibrosis via activation of Sirt1, leading to the inactivation of NF-κB and inhibition of TNF-α [32,33]. In contrast, available evidence was not sufficient to show a beneficial effect of resveratrol in decreasing the cytokines level among NAFLD patients, the trial by Chen et al [11] was the only published clinical trial which demonstrated a significant reduction in TNF-α and IL-6 in the resveratrol group.…”

Section: Summary Of the Main Resultsmentioning

confidence: 99%

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

show abstract

Section: Summary Of the Main Resultsmentioning

confidence: 99%

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

show abstract

“…1O, Q; Jeon et al 2012) and KC recruitment ( Fig. 1P; Chan et al 2011Chan et al , 2014, decreases TNF-α levels (Bujanda et al 2008;Chan et al 2014;Chang et al 2012;Li et al 2014), as well as inhibits the NF-κB pathway (Chang et al 2012;Li et al 2014). In accordance, it was previously shown that RSV treatment protects against LPS-induced cytotoxicity in rat hepatic KC ( Fig.…”

Section: Resveratrol Inhibits Ethanol-induced Liver Oxidative Stress mentioning

confidence: 96%

Dual effect of red wine on liver redox status: a concise and mechanistic review

2015

View full text Add to dashboard Cite

Chronic ethanol consumption is a strong risk factor for the development of liver disease. Multiple mechanisms are involved in ethanol-mediated liver injury; oxidative stress being pointed has an important factor. However, it should be noted that moderate consumption of red wine has been associated with hepatoprotective effects, mainly due to the antioxidant effect of resveratrol, one of its polyphenolic compounds. In this paper, the potential molecular mechanisms through which the protective effects of resveratrol counteract the oxidative effect of ethanol and the way as this dual effect impacts liver oxidative stress are reviewed. Mechanistic evaluation of modulation of oxidative signaling pathways by ethanol and resveratrol may explain the pathogenesis of various liver diseases and ultimately to disclose possible pharmacological therapies.

show abstract

“…"lso cafeine, of which epidemiological data suggest a protective efect on N"FLD, was shown to induce autophagy dose dependently with increased lipid clearance [35,63]. Finally, the antioxidants resveratrol [64,65] and tert-butylhydroquinone [66], but also metformin [67], were able to atenuate hepatic steatosis by inducing autophagy via activation of "MPK/ Sirtuin-1. Other possible mechanisms parallel to changes in autophagy that might explain the observed efects are formally not excluded, as illustrated by the reduced expression of genes related to ER stress and inlammation and increased expression of genes involved in lipid oxidation in zebraish exposed to cafeine [63].…”

Section: Autophagy As a Lipolytic Mechanismmentioning

confidence: 97%

Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD)

Kwanten¹,

Martinet²,

Francque³

2016

Autophagy in Current Trends in Cellular Physiology and Pathology

View full text Add to dashboard Cite

Abstract"utophagy is a mechanism involved in cellular homeostasis under basal and stressed conditions delivering cytoplasmic content to the lysosomes for degradation to macronutrients. The potential role of autophagy in disease is increasingly recognised and investigated. To date, a key role of autophagy in hepatic lipid metabolism is recognised and dysfunctional autophagy might be an underlying cause of non-alcoholic faty liver disease N"FLD . Nevertheless, the exact role of autophagy in lipid metabolism remains controversial, with both a lipolytic function of autophagy and lipogenic function reported. This chapter aims to review the current knowledge on autophagy in N"FLD, with a special focus on its role in hepatic lipid metabolism, hepatic glucose metabolism and insulin resistance, steatohepatitis, hepatocellular injury and hepatic ibrogenesis. Finally, interaction with another cellular homeostatic process, the unfolded protein response UPR , will be briely discussed.

show abstract

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

Cited by 125 publications

References 29 publications

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Dual effect of red wine on liver redox status: a concise and mechanistic review

Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD)

Contact Info

Product

Resources

About